Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel